Published in Medical Letter on the CDC and FDA, September 26th, 2004
The 2-year agreement provides for further testing of AVI's Neugene antisense therapeutics, which have been shown to be highly effective in killing all four serotypes of dengue virus in preliminary studies. Dengue viruses are endemic in most tropical countries worldwide, and are an emerging infectious disease threat to North America.
"This collaboration with the CDC and our recently announced anti-viral collaboration with the U.S. Army Medical Research Institute of Infectious...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.